Ballicules.com

Simvastatin

ZOCOR

What it isHMG-CoA reductase inhibitor for hyperlipidemia and ASCVD prevention; a moderate-intensity statin.

Why this oneIts low cost and long familiarity are offset by more CYP3A4 restrictions than nearly any other statin.

What limits itStrong CYP3A4 inhibitors can precipitate myopathy; common cardiovascular drugs impose dose ceilings. Take it in the evening.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
HyperlipidemiaAdults20 mg20–40 mg40 mg (80 mg QD only if tolerated chronically ≥12 mo)
HeFHPediatric ≥10 yr10 mg10–40 mg40 mg

Renal Severe impairment (CLcr 15–29): start 5 mg QD; no adjustment for mild–moderate

Hepatic Contraindicated in acute liver failure or decompensated cirrhosis

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy May cause fetal harm; discontinue when pregnancy is recognized

Lactation Breastfeeding not recommended during treatment

NO BOXED WARNINGS

Principal riskMyopathy, dose-related and worsened by CYP3A4 inhibitors

Cost, est. cash$4–$80/month

Generic entry2006

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryX

Defining liabilityMyopathy/rhabdomyolysis and hepatotoxicity; interaction burden varies by agent.

Mechanism of action: Simvastatin ballicule

Simvastatin ballicule: receptor binding, kinetics and half-life diagram

Open Simvastatin in the interactive console ↗

Memory aids: mascots and interaction avatars

Simvastatin ZOCOR mascot mnemonic cartoon
“Zoo Corp’s Simba-statin”
Simvastatin CYP3A4 substrate avatar
CYP3A4 substrate
Simvastatin OATP substrate avatar
OATP substrate

Open Simvastatin in the interactive console ↗